YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 - TransCon CNP NDA submission for achondroplasia planned for Q1 2025 ...
Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback